ALK and lung carcinoma: While we were not able to assess potential variation in duration of treatment among the three murine EML4-ALK immunocompetent models as this would likely require many months of daily oral alectinib therapy in tumor-bearing mice, we postulate that variation in the composition of the TME among individual tumor models may account for the range of therapy durations observed in oncogene-defined subsets of lung cancer patients.